Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | AKT2 | P31751 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134324 | 0.84 | ADORA1 (0.47) | KMT2AADORA2A | |
| SCHEMBL6135183 | 0.82 | MERTK (0.42) | ADORA2ATP53MERTK | |
| SCHEMBL6133485 | 0.82 | ALDH1A1 (0.44) | NPSR1MEN1KMT2ATP53MERTK | |
| SCHEMBL6133535 | 0.80 | MERTK (0.34) | ADORA2ATP53MERTK | |
| SCHEMBL6134812 | 0.80 | MERTK (0.56) | MEN1KMT2AMERTK | |
| SCHEMBL6133753 | 0.79 | TP53 (0.38) | KMT2AMAPTADORA2ATP53MERTK | |
| SCHEMBL6133749 | 0.78 | TP53 (0.44) | RXFP1TP53MERTK | |
| SCHEMBL6134592 | 0.78 | ADORA1 (0.47) | THRBMEN1KMT2AMAPTADORA2A | |
| SCHEMBL6134310 | 0.77 | GAA (0.45) | RXFP1MAPTADORA2ATP53MERTK | |
| SCHEMBL6134738 | 0.77 | ADORA3 (0.39) | MEN1KMT2AMAPTADORA2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | NTRK1 4294/4885THRB 1570/4885RXFP1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.